These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets. Allen WJ; Fochtman BC; Balius TE; Rizzo RC J Comput Chem; 2017 Nov; 38(30):2641-2663. PubMed ID: 28940386 [TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation. Allen WJ; Yi HA; Gochin M; Jacobs A; Rizzo RC Bioorg Med Chem Lett; 2015 Jul; 25(14):2853-9. PubMed ID: 26013847 [TBL] [Abstract][Full Text] [Related]
8. Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: quantitative correlation with experiment. Strockbine B; Rizzo RC Proteins; 2007 May; 67(3):630-42. PubMed ID: 17335007 [TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics modeling the synthetic and biological polymers interactions pre-studied via docking: anchors modified polyanions interference with the HIV-1 fusion mediator. Tsvetkov VB; Serbin AV J Comput Aided Mol Des; 2014 Jun; 28(6):647-73. PubMed ID: 24862639 [TBL] [Abstract][Full Text] [Related]
10. Anti-HIV-1 Activity Prediction of Novel Gp41 Inhibitors Using Structure-Based Virtual Screening and Molecular Dynamics Simulation. Sepehri S; Saghaie L; Fassihi A Mol Inform; 2017 Mar; 36(3):. PubMed ID: 27730744 [TBL] [Abstract][Full Text] [Related]
11. Identification of small molecule inhibitors of botulinum neurotoxin serotype E via footprint similarity. Zhou Y; McGillick BE; Teng YG; Haranahalli K; Ojima I; Swaminathan S; Rizzo RC Bioorg Med Chem; 2016 Oct; 24(20):4875-4889. PubMed ID: 27543389 [TBL] [Abstract][Full Text] [Related]
12. Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency. Andrianov AM; Kashyn IA; Tuzikov AV J Bioinform Comput Biol; 2018 Apr; 16(2):1840007. PubMed ID: 29439644 [TBL] [Abstract][Full Text] [Related]
13. Origins of resistance to the HIVgp41 viral entry inhibitor T20. McGillick BE; Balius TE; Mukherjee S; Rizzo RC Biochemistry; 2010 May; 49(17):3575-92. PubMed ID: 20230061 [TBL] [Abstract][Full Text] [Related]
14. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. Debnath AK; Radigan L; Jiang S J Med Chem; 1999 Aug; 42(17):3203-9. PubMed ID: 10464007 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, Molecular Docking and Molecular Dynamics Simulation of 2- Thioxothiazolidin-4-One Derivatives against Gp41. Tamiz N; Mostashari-Rad T; Najafipour A; Claes S; Schols D; Fassihi A Curr HIV Res; 2021; 19(1):47-60. PubMed ID: 32885756 [TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of shape similarity based pose prediction method in D3R Grand Challenge 2015. Kumar A; Zhang KY J Comput Aided Mol Des; 2016 Sep; 30(9):685-693. PubMed ID: 27484214 [TBL] [Abstract][Full Text] [Related]
17. Paramagnetic relaxation assisted docking of a small indole compound in the HIV-1 gp41 hydrophobic pocket. Gochin M; Zhou G; Phillips AH ACS Chem Biol; 2011 Mar; 6(3):267-74. PubMed ID: 21155611 [TBL] [Abstract][Full Text] [Related]